Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 July 2019Website:
http://www.mirumpharma.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 22:11:25 GMTDividend
Analysts recommendations
Institutional Ownership
MIRM Latest News
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI. Jessica Fye - JP Morgan Dae Gon Ha - Stifel Brian Skorney - Baird David Lebowitz - Citi Thomas Yip - H.C.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.92 per share a year ago.
Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC.
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
- 1(current)
- 2
What type of business is Mirum Pharmaceuticals?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
What sector is Mirum Pharmaceuticals in?
Mirum Pharmaceuticals is in the Healthcare sector
What industry is Mirum Pharmaceuticals in?
Mirum Pharmaceuticals is in the Biotechnology industry
What country is Mirum Pharmaceuticals from?
Mirum Pharmaceuticals is headquartered in United States
When did Mirum Pharmaceuticals go public?
Mirum Pharmaceuticals initial public offering (IPO) was on 18 July 2019
What is Mirum Pharmaceuticals website?
https://www.mirumpharma.com
Is Mirum Pharmaceuticals in the S&P 500?
No, Mirum Pharmaceuticals is not included in the S&P 500 index
Is Mirum Pharmaceuticals in the NASDAQ 100?
No, Mirum Pharmaceuticals is not included in the NASDAQ 100 index
Is Mirum Pharmaceuticals in the Dow Jones?
No, Mirum Pharmaceuticals is not included in the Dow Jones index
When was Mirum Pharmaceuticals the previous earnings report?
No data
When does Mirum Pharmaceuticals earnings report?
The next expected earnings date for Mirum Pharmaceuticals is 28 February 2025